Dornase Alfa Inhalant Product

Phase 3Small molecule

UUniversity Hospital, Strasbourg, France

Dornase Alfa Inhalant Product is one of 60 small molecule programs targeting Respiratory Failure. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory FailureActive, not recruiting

COVID-19Active, not recruiting

Respiratory FailurePhase 3

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Spikevax

Moderna

Preclinical

21 2

Dornase Alfa Inhalant Product

UUniversity Hospital, Strasbourg, France

Phase 3

1 3

Calciferol

Alnylam Pharmaceuticals

Activella

Aprotinin

1 6

Antithrombin-III

Octapharma

Preclinical

1 7

Interferon-Gamma

SSPP Pharmaclon Ltd.

Preclinical

1 8

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

1 9

Blood Taken

HHospices Civils de Lyon

Preclinical

1 10

Moderna COVID-19 Vaccine

Moderna

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Respiratory Failure

NCT03368092

Clinical

Trials by Indication[1]

Respiratory Failure1 trial

Inhaled Dornase Alpha to Reduce Respiratory Failure After Severe Trauma

Recruiting·UUniversity Hospital, Strasbourg, France·Phase 3·NCT03368092·500 enrolled

COVID-191 trial

Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19

Unknown status·—·N/A·NCT05279391·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Dornase Alfa Inhalant Product. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dornase Alfa Inhalant Product compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dornase Alfa Inhalant Product. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Strasbourg, France company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity Hospital, Strasbourg, France

Dornase Alfa Inhalant Product

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Respiratory Failure1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News